Your session is about to expire
← Back to Search
Tolebrutinib for Multiple Sclerosis
Study Summary
This trial is testing a new drug for safety and effectiveness in treating RMS.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am taking blood thinners but can stop them before starting the study drug.I have not received any live vaccines between my last and first study visits.I am taking medication that strongly affects liver enzymes.I am using effective birth control or am not able to have children due to surgery or menopause.
- Group 1: SAR442168
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the upper age limit for this clinical trial set at 18 years or above?
"In accordance with the trial's eligibility conditions, only participants who are aged 18-55 may join."
What is the total number of medical facilities that are conducting this investigation?
"This trial is currently being implemented at 10 medical sites across the United States. The cities of Dayton, Cullman and Knoxville are among those hosting patients for this study; other locations may be closer to you for your convenience."
What ultimate goals are being sought by this clinical research endeavor?
"The primary metrics evaluated in this study over the Baseline to final follow-up period ( Month 60 plus 8 weeks) are Participants with Potentially Clinically Significant Abnormalities. Additionally, Secondary endpoints encompass Change in Expanded Disability Status Scale (EDSS), Number of participants wih relapse (Annualized Relapse rate), and Total number of Gd-enhancing T1-hyperintense lesions. The former is measured by standard EDSS assessments across 7 functional domains, while ambulation score will also be recorded."
Is there still an opportunity to enroll in this research endeavor?
"According to the data presented on clinicaltrials.gov, this study has completed its recruitment phase as of May 10th 2022 and is no longer searching for participants. However, there are still 549 other trials available that may be suitable for prospective volunteers."
Could you enumerate the potential hazards of Tolebrutinib consumption?
"Tolebrutinib has been classified as a 2 on Power's scale due to the lack of evidence for efficacy, but there is some data indicating it may be safe."
What are the requirements for participating in this clinical investigation?
"To be eligible for this medical trial, applicants must have been diagnosed with multiple sclerosis and between the ages of 18-55. A total of 125 participants will be accepted into the program."
Share this study with friends
Copy Link
Messenger